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Abstract
Background: We report the characterisation of the variable large protein (vlp) gene expressed
by clinical isolate A1 of Borrelia recurrentis; the agent of the life-threatening disease louse-borne
relapsing fever.
Methods: The major vlp protein of this isolate was characterised and a DNA probe created. Use
of this together with standard molecular methods was used to determine the location of the vlp1B.
recurrentis A1 gene in both this and other isolates.
Results: This isolate was found to carry silent and expressed copies of the vlp1B. recurrentis A1 gene
on plasmids of 54 kbp and 24 kbp respectively, whereas a different isolate, A17, had only the silent
vlp1B. recurrentis A17 on a 54 kbp plasmid. Silent and expressed vlp1 have identical mature protein
coding regions but have different 5' regions, both containing different potential lipoprotein leader
sequences. Only one form of vlp1 is transcribed in the A1 isolate of B. recurrentis, yet both 5'
upstream sequences of this vlp1 gene possess features of bacterial promoters.
Conclusion: Taken together these results suggest that antigenic variation in B. recurrentis may
result from recombination of variable large and small protein genes at the junction between
lipoprotein leader sequence and mature protein coding region. However, this hypothetical model
needs to be validated by further identification of expressed and silent variant protein genes in other
B. recurrentis isolates.
Background
Expression of a variant surface antigen is utilised by a wide
variety of pathogenic micro-organisms to evade the im-
mune defences of the host, thereby prolonging the dura-
tion of infection and increasing the likelihood of
transmission. In the early part of the last century micro-
biologists first observed this process in relapsing fever
caused by Borreliae as the spirochaetes recovered from
each relapse differed serologically. The classical molecular
description of this phenomenon comes from studies of
Borrelia hermsii, an aetiologic agent of tick-borne relapsing
fever. Variable major proteins are the dominant surface
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antigen [1], which are involved in evasion of the host's
immune system as Borreliae emerging at each relapse ex-
press a different antigenic form [2]. Detailed molecular
analysis has revealed that the corresponding genes are ar-
ranged into silent and expressed copies on different plas-
mids [3,4]. Antigenic variation occurs by replacement of
the entire open reading frame of the expressed gene by a
previously silent one, or by activation of a previously si-
lent downstream gene [3–8]. Recently the variant major
proteins, formerly denoted Vmp, have been divided into
two groups based on size, namely the variant large pro-
teins (encoded by vlp genes of typical size 1 kbp) and var-
iant small proteins (encoded by vsp genes of typical size
0.6 kbp).
The present study considers the related organism B. recur-
rentis, the causative agent of louse-borne relapsing fever
(LBRF). LBRF is a systemic inflammatory disease, which,
if untreated, is associated with mortality rates of up to
40% [9]. This is reduced to 2–4% by use of antibiotics. Al-
though the disease is relatively localised at present, with
an endemic focus in Ethiopia, the potential for epidemics
remains. Indeed the most recent outbreak occurred in the
Sudan [10]. The disease is characterised by high fevers due
to production of inflammatory mediators by the host in
response to spirochaetal toxins [11,12]. It has been shown
that the major pro-inflammatory molecule of B. recurren-
tis clinical isolate A1 is highly homologous to Vlp12B.
hermsii HS1, and is here referred to as Vlp1B. recurrentis A1[13].
Studies of the molecular biology of B. recurrentis have
been hampered by the lack of an animal model. The first
cultivation of a clinical isolate in vitro was achieved in
1993 [14] and to date eighteen clinical isolates have been
characterised by their plasmid profile and by the expres-
sion of a putative Vlp or Vsp [15]. As the first step to study
antigenic variation in B. recurrentis, we report the com-
plete organisation and characterisation of vlp1B. recurrentis
A1 gene coding for the variant surface antigen of this iso-
late.
Methods
Borrelia recurrentis isolates
Isolates A1 and A17 from Ethiopian patients with LBRF
and were subcultured in vitro as previously described
[14,15]. There was no change in protein profiles or plas-
mid DNA banding patterns during this investigation com-
pared with those observed for each isolate following
original isolation from patients described previously
[14,15].
Nucleic acid purification
Plasmid and chromosome-rich DNA fractions were pre-
pared as described [30]. Total RNA was purified using the
TRI Reagent method [31] (Sigma) and resuspended in
RNase-free water.
Probe labelling
The 715 bp PCR product amplified from part of the ex-
pressed  vlp1B. recurrentis A1 gene [13] was labelled with
α32P-dCTP by random-priming (Amersham-Pharmacia
Biotech). Oligonucleotide probes (LLS1, CACCA CTAT-
CATCATCATCAAT and LLS2, TCATCACCATCACCAG-
CACC) were labelled with γ32P-ATP by enzymatic
phosphorylation with polynucleotide kinase (Roche Mo-
lecular Biochemicals; the sequences corresponding to the
probes LLS1 and LLS2 are double-underlined in Fig. 2).
All radioactive probes were purified (Chromaspin-10,
Clontech) prior to hybridisation.
Library construction and screening
Plasmid DNA from isolate A1 was digested to completion
with HindIII. Fragments of relevant sizes were gel purified
using QIAEXII kit (Qiagen) and ligated in pBluescript lin-
earised with HindIII. A portion of the ligation reaction
was used to transform library efficient E. coli DH5α strain
(GIBCO-BRL). Colonies were lifted onto Hybond-N
membranes (Amersham-Pharmacia Biotech) and hybrid-
ised at high stringency with the 715 bp vlp1 probe as de-
scribed [32]. After a second round of screening, positive
clones were sequenced on an ABI377 automated sequenc-
er using BigDye Terminator (Applied Biosystem). Se-
quences were assembled and analysed using the
Wisconsin Genetics Computer Group, Madison, WI soft-
ware package.
Southern hybridisation
Eight hundred nanograms of DNA were digested with a
range of restriction enzymes. Digestion products were
fractionated on a 1% agarose TAE gel. After electrophore-
sis the gel was treated as described [32] prior to capillary
transfer onto Hybond-N membranes (Amersham-Phar-
macia Biotech) in 10 × SSC overnight. Following UV-
crosslinking, blots were hybridised in Rapid-Hyb solution
(Amersham-Pharmacia Biotech) and washed using high
stringency conditions (0.5 × SSC/0.1% SDS and 0.1 ×
SSC/0.1% SDS at 65°C each for 15 minutes).
Field inversion gel electrophoresis
One microgram of plasmid DNA from isolates A1 or A17
were separated by field inversion gel electrophoresis on a
1% agarose, 0.5 × TBE gel using the predefined pro-
gramme P1 to separate DNA fragments between 150 kbp
and 5 kbp (Biorad).
Northern hybridisation
One and a half microgram of total RNA were separated on
a formaldehyde agarose gel and transferred onto a Hy-
bond-N membrane in 10 × SSC. Following UV-crosslink-BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/25
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Figure 1
vlp1B. recurrentis A1 is plasmid encoded and duplicated in isolate A1. A: Plasmid (lane 1 to 4) and chromosome-rich (lane
5 to 8) DNA were digested with EcoRI (lane 1 and 5), HindIII (lane 2 and 6), XbaI (lane 3 and 7), and DraI (lane 4 and 8), trans-
ferred to a membrane and hybridised under high stringency with the 715 bp vlp1 probe. B: Plasmid DNA from isolate A1 (lane
1 to 3) and isolate A17 (lanes 4 to 6) and total DNA from isolate A17 (lane 7) were digested with HindIII (lane 1 and 4), EcoRI
(lane 2, 5, and 7), XbaI (lane 3 and 6), and treated as described above. C: Intact plasmids from isolate A1 (lane 1) and isolate
A17 (lane 2) were separated by field inversion gel electrophoresis (predefined program P1, Biorad) and treated as described
above.
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Figure 2
Ungapped DNA sequence alignment of the two forms of vlp1B. recurrentis A1 The upper row represents the sequence
derived from the slower migrating 54 kbp plasmid of figure 1C. The sequence corresponding to the UP element consensus
found in the bottom row sequence is italicised. The putative '-35' and '-10' elements and ribosome binding sites are underlined.
Translation start sites are shown in bold. Region complementary to LLS1 and LLS2 probes are double-underlined. Accession
number for both sequences are given in the methods section.
1    GAGCTCTCTTTTTTTATTTGCAGTATTGTGTATGTTATTAAATCCTCATT
   | | ||||||| |||    | || | | | || ||      | |||
1    TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGGTTATT
50   TATTTGTTTTTTGCTTTTAAAGATAAGCTAGAAAAAATAAAAATAAGGAG
     || || |   |    |||| |  |||  |         |||| |   ||
50   TAATTATAAATAAAATTTATAATTAAAATTTTTTTGTAAAAACTTGAGAA
-35
-35
100  GCGAAGAAAATGAAGAGAGAAGAAAAAAAAGGTATGAGAGAAATAGAGAG
        ||   | || |          || | | |   || | | |   | |
100  ATAAAATTATTGTACTATCTTTTTAAGATAAGCTAGAAAAATAATAAAAA
-10
-10                 RBS      +1
150  AGTGAGAGAGAGGAGATATAAATAGAGTGAATAATATAGGGAATAGAATG
     | |  |||     |   || || ||||  |  ||   ||  |  | ||   
150  AATAGGAGGCGAAAAGAATGAAGAGAGGAATAAAAGGAGAAATGATAAAT
         RBS         +1
200  AGGATTAAGGGAATAATATTGATGATGATGATAGTGGTGGGATGTAATAG
     ||  | | |  ||||||  || || ||||| |  || |||||||||||||
200  AGAGTGATGATAATAATGGTGCTGGTGATGGTGATGATGGGATGTAATAG
250  TGGAGGAGGAATAAAGGAAGGAGAGGGAGAGAGTTCTCAGAGTAAATTTT
     ||||||||||||||||||||||||||||||||||||||||||||||||||
250  TGGAGGAGGAATAAAGGAAGGAGAGGGAGAGAGTTCTCAGAGTAAATTTT
300  TGAAGTCTATTATTGGTTTAAGGAATGAATTTTTGAATGTTTTTACTTCT
     ||||||||||||||||||||||||||||||||||||||||||||||||||
300  TGAAGTCTATTATTGGTTTAAGGAATGAATTTTTGAATGTTTTTACTTCT
350  TTTGGCGATATGGTTGGAGGAATATTAGGGTTTAATGCTGTTAAGTCAGA
     ||||||||||||||||||||||||||||||||||||||||||||||||||
350  TTTGGCGATATGGTTGGAGGAATATTAGGGTTTAATGCTGTTAAGTCAGA
400  TGATAAGAGAAGTAAAGTGGGGGAACATTTTAAGACTATAGGAGATGGAT
     ||||||||||||||||||||||||||||||||||||||||||||||||||
400  TGATAAGAGAAGTAAAGTGGGGGAACATTTTAAGACTATAGGAGATGGAT
450  TAAAGAGCACTAAGGATAAATTGGATGAGTTATCAAAACAAATAGTTTCG
     ||||||||||||||||||||||||||||||||||||||||||||||||||
450  TAAAGAGCACTAAGGATAAATTGGATGAGTTATCAAAACAAATAGTTTCG
500  ACTTCTAATGCTGATATTAAAGGAGTAGAAGCTGTTATTCAAGGCACTAG
     ||||||||||||||||||||||||||||||||||||||||||||||||||
500  ACTTCTAATGCTGATATTAAAGGAGTAGAAGCTGTTATTCAAGGCACTAG
550  TGAAGTGATTGCAAAGTTGATTACTTCTATAACTGAGCTTGCTGGAATAA
     ||||||||||||||||||||||||||||||||||||||||||||||||||
550  TGAAGTGATTGCAAAGTTGATTACTTCTATAACTGAGCTTGCTGGAATAA
600  CTAAAGAAGGTAATGTTGATATTGGTGATGCTGGTACTGCTGGTAGTGCT
     ||||||||||||||||||||||||||||||||||||||||||||||||||
600  CTAAAGAAGGTAATGTTGATATTGGTGATGCTGGTACTGCTGGTAGTGCT
650  GCTGCAGTAGCTGCTGACAAGGCTAGTGTTGAGGCTATTATTAAAGGTGT
     ||||||||||||||||||||||||||||||||||||||||||||||||||
650  GCTGCAGTAGCTGCTGACAAGGCTAGTGTTGAGGCTATTATTAAAGGTGT
700  GAAAGAAATAGTTGAGACTGCAGAGAAGTCTGGAGTGAAGATTGAAAAAG
     ||||||||||||||||||||||||||||||||||||||||||||||||||
700  GAAAGAAATAGTTGAGACTGCAGAGAAGTCTGGAGTGAAGATTGAAAAAG
750  GGAATGCTGGGAATAGTGTAGCAAATGGTAATGGACCTAAAGCAGTGGTT
     ||||||||||||||||||||||||||||||||||||||||||||||||||
750  GGAATGCTGGGAATAGTGTAGCAAATGGTAATGGACCTAAAGCAGTGGTT
800  CACAATGTTCAGGCTACTGCAGGTGACGCTACTAAATTGGCTGGTGAAGT
     ||||||||||||||||||||||||||||||||||||||||||||||||||
800 CACAATGTTCAGGCTACTGCAGGTGACGCTACTAAATTGGCTGGTGAAGT
850  GGCTAAGGCTGATCCATGGGCAATGATTGATAAGATAAAAAATGCTAAGA
     ||||||||||||||||||||||||||||||||||||||||||||||||||
850  GGCTAAGGCTGATCCATGGGCAATGATTGATAAGATAAAAAATGCTAAGA
900  CTAAAAATAATGTTGCGCCTGCTGCTAATGATGATGCTGGACAATTAGCT
     ||||||||||||||||||||||||||||||||||||||||||||||||||
900  CTAAAAATAATGTTGCGCCTGCTGCTAATGATGATGCTGGACAATTAGCT
950  ACTGCTACTGGTGCTAATGACAACGGATCTGCATCTACCAATGCGGATTT
     ||||||||||||||||||||||||||||||||||||||||||||||||||
950  ACTGCTACTGGTGCTAATGACAACGGATCTGCATCTACCAATGCGGATTT
1000 AGCGGCTTCTGTTGCACTAAAAGCTATGACAAAAGGGGGTAAATTTACTC
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1000 AGCGGCTTCTGTTGCACTAAAAGCTATGACAAAAGGGGGTAAATTTACTC
1050 AACCTGCTGCTAATGAAGATGGTGCAATTAAGGCTGCTGCGGCTAGTGCA
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1050 AACCTGCTGCTAATGAAGATGGTGCAATTAAGGCTGCTGCGGCTAGTGCA
1100 GTAAATAAGGTATTAGGAATATTGGATATGATTATTAGGAAAGCAGTAAA
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1100 GTAAATAAGGTATTAGGAATATTGGATATGATTATTAGGAAAGCAGTAAA
1150 TCTTGAACTTGATAAAGTGAAAGAAGCAGTTAAAGGAATAAGATATTCTG
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1150 TCTTGAACTTGATAAAGTGAAAGAAGCAGTTAAAGGAATAAGATATTCTG
1200 AGACATCTGGAAGTAATGCTACAGAAGCTGGCACTATTCAAACTTCTACT
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1200 AGACATCTGGAAGTAATGCTACAGAAGCTGGCACTATTCAAACTTCTACT
1250 GTTAAATAAATCGTAAGATTAAATAATAAAAACAATTAAGGAAAGCAGCG
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1250 GTTAAATAAATCGTAAGATTAAATAATAAAAACAATTAAGGAAAGCAGCG
1300 TCATCTTTATGCATGAGAGTTGTTTTCCTTTTTTGTATTTTATTATGTCT
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1300 TCATCTTTATGCATGAGAGTTGTTTTCCTTTTTTGTATTTTATTATGTCT
1350 CGTTGCAACATTTATTATTTTTTTATTTATCATGTGCTAATAATAAATCT
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1350 CGTTGCAACATTTATTATTTTTTTATTTATCATGTGCTAATAATAAATCT
1400 GGAGTTCTGGCTACTGCTATTGCGGCTGCTAATAGTAGTACTGGTGCAGC
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1400 GGAGTTCTGGCTACTGCTATTGCGGCTGCTAATAGTAGTACTGGTGCAGC
1450 TACTAATGCGGATCTAGCAGCAGCAGTAGCTCTTAAAGCCAATTACTAAA
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1450 TACTAATGCGGATCTAGCAGCAGCAGTAGCTCTTAAAGCCAATTACTAAA
1500 ACTGGTAAATTTAGTGATGCTGCTAATGATGTTGGAGCAGTTAAGGCAGC
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1500 ACTGGTAAATTTAGTGATGCTGCTAATGATGTTGGAGCAGTTAAGGCAGC
1550 AGCAACAAGTGCAGTCAATAAGGTATTAGGAATACTTAATTTAATAATTA
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1550 AGCAACAAGTGCAGTCAATAAGGTATTAGGAATACTTAATTTAATAATTA
1600 GGAAAACAGTAAGTATTAATATAAATAAGATAAGATAAGAGAAGCTGTTA
     ||||||||||||||||||||||||||||||||||||||||||||||||||
1600 GGAAAACAGTAAGTATTAATATAAATAAGATAAGATAAGAGAAGCTGTTA
1650 AGGGAATACAGTACTCTGAAACAGTTGGAGCTAATTTAAACCGAAGCTT
  |||||||||||||||||||||||||||||||||||||||||||||||||
1650 AGGGAATACAGTACTCTGAAACAGTTGGAGCTAATTTAAACCGAAGCTTBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/25
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ing, blots were hybridised in Rapid-Hyb solution
(Amersham-Pharmacia Biotech) and washed using high
stringency. When labelled oligonucleotides were used as
probes, hybridisations were carried out at 1°C below the
calculated melting temperature.
Database accession numbers
Expressed vlp1B. recurrentis A1: AJ237608; Silent vlp1B. recur-
rentis A1: AJ237609.
Results
vlp1B. recurrentis A1 is plasmid encoded
A probe encoding a 715 bp portion of the expressed vlp1B.
recurrentis A1, generated by microsequencing [13] was used
to characterise vlp1 in two distinct B. recurrentis isolates.
Plasmids and chromosome-rich extracts from isolate A1
were digested with several restriction endonucleases. This
was followed by Southern hybridisation with the 715 bp
vlp1 probe. Restriction enzymes that do not cleave the re-
gion of DNA encompassing the hybridisation probe were
used.
As shown in figure 1A, two bands were detected in the
plasmid extract under high stringency hybridisation con-
ditions. A third band of 43 kbp was observed at lower
stringency conditions (data not shown). In contrast, the
chromosomal-rich extract gave only weak hybridisation
signals, probably caused by contaminating plasmid DNA.
When the same experiment was performed on total and
plasmid DNA from isolate A17 under high stringency,
only one band could be detected (fig. 1B; lane 4 to 7).
To confirm these findings, plasmids from both isolates
were separated using field inversion gel electrophoresis
(FIGE). Ethidium bromide staining revealed six major
plasmid species in the range of 10 to over 100 kbp (not
shown). Hybridisation under high stringency with the
vlp1 probe detected a common band between isolate A1
and A17 corresponding to a plasmid of about 54 kbp (fig.
1C). This was also detected by the vlp1 probe in 10 further
isolates possessing the 54 kbp plasmid. However, an extra
band was detected in isolate A1 corresponding to a plas-
mid of about 24 kbp. Similarly, this 24 kbp band was also
present in three other isolates falling into the same group
of B. recurrentis[15]. Densitometry analysis showed that
the signal intensity of the 24 kbp plasmid was about 3 to
4 times higher than the intensity given by the 54 kbp plas-
mid. These results show that vlp1B. recurrentis is plasmid-en-
coded and in isolate A1 the two vlp1 loci are localised on
different plasmids. These results also raise the possibility
that silent and expressed copies of vlp1 are present in B. re-
currentis A1, whereas isolate A17 possesses only the silent
copy.
Sequence of the vlp1B. recurrentis A1 loci
To investigate further the vlp1B. recurrentis loci we screened a
partial library of isolate A1 plasmid DNA with the vlp1
probe. Positive clones of two different sizes were ob-
tained, corresponding to thevlp1 loci carried on the 54 and
24 kbp plasmids depicted in figure 1C. The ungapped
alignment of the two copies of vlp1B. recurrentis A1 is present-
ed in figure 2; sequence 1 is derived from the slower mi-
grating 54 kbp plasmid. Overall these two sequences are
about 65% A/T rich in keeping with the low G/C content
of borrelial DNA [16]. There is an extensive region (1461
bp) of strict identity that starts in the vlp1B. recurrentis open
reading frame and extends beyond the stop codon. An ad-
ditional feature of this region is the presence downstream
of the open reading frame starting at nt1385 of a 300 bp
segment that possesses 73% identity with the vlp1B. recur-
rentis A1 gene itself. Analysis of the translated sequences
showed that the N-terminal component is not conserved,
the identity between the two sequences starts one residue
before the unique cysteine. Both N-terminal sequences
code for a putative lipoprotein leader signal sequence
[17,18], consistent with the finding that Vlp1B. recurrentis A1
has a lipid modification [13]. The divergence in the 5' end
of the vlp1 coding region extends upstream where the two
sequences are highly dissimilar. Interestingly, the up-
stream region of sequence 2 is richer in pyrimidine than
that of sequence 1 (pyrimidine content of 59% and 34%
respectively). However, both upstream regions possess a
potential ribosome binding site and imperfect -10 and -35
regions, the consensus recognition site for σ 70 RNA
polymerase. In addition sequence 2 has a nearly perfect
consensus UP element [19], the binding site for the C-ter-
minal domain of the RNA polymerase, and an unusually
long uninterrupted tract of 42 dT. Of note, another poten-
tial translational start is found in sequence 2 at nucleotide
191, with the -10 region starting at position 141 (not
shown).
Taken together these results show that the two vlp1B. recur-
rentis A1 genes code for the same mature protein but have a
different lipoprotein leader sequence. In addition, the
presence of putative promoter features in upstream re-
gions of both genes leaves the question of silent and ex-
pressed copies unresolved.
vlp1B. recurrentis is organised into silent and expressed cop-
ies
The total RNA were extracted from isolates A1 and A17 re-
spectively, and Northern hybridisation was performed us-
ing oligonucleotide probes specific for the two
lipoprotein leader signal sequences (LLS1 & LLS2), and
the partial vlp1 probe. When the vlp1 probe was used, a
strong hybridisation signal corresponding to a mRNA of
around 1.2 kb was obtained only from isolate A1 (Fig. 3).
This illustrates that vlp1B. recurrentis A1 is expressed only inBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/25
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Figure 3
vlp1B. recurrentis A1 is organised into silent and expressed copies. Total RNA from isolates A1 and A17 were separated
on an agarose gel, blotted to a membrane and hybridised with specific probes. A: 715 bp vlp1; B: LLS1-specific probe; C: LLS2-
specific probe
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isolate A1, but not in A17. No signal was detected when
the oligonucleotide probe LLS1 specific for leader se-
quence 1 was used. In contrast, the LLS 2 specific probe
detected a 1.2 kb RNA corresponding to vlp1B. recurrentis A1
message only in RNA extracted from isolate A1. Of note,
probe LLS2 detected a message of about 800 b only in iso-
late A17 RNA. These results demonstrate that there is a si-
lent and expressed copy of vlp1 in B. recurrentis A1;
sequence 2 in figure 2 representing the expressed copy of
vlp1B. recurrentis A1.
Discussion
The dominant surface antigen of Borrelia is a variant pro-
tein encoded by a large repertoire of genes, only one of
which is expressed at anyone time. In contrast to other
borreliae, the study of antigenic variation in B. recurrentis
has been hampered by the lack of an animal model of in-
fection. Isolates can only be recovered from patients and
further characterised in vitro. Nevertheless, as the first step
to better understand this phenomenon, we report the first
complete characterisation of vlp1B. recurrentis A1 gene from a
clinical isolate. This gene has common features with vari-
ant protein genes from other Borrelia species but has some
intriguing features.
In isolate A1, which expresses the Vlp1B. recurrentis A1 pro-
tein [13,15], there are two copies of vlp1B. recurrentis A1, one
on a 54 kbp plasmid and the other on a 24 kbp plasmid.
This is reinforced by the observation of hybridisation with
these two plasmids and the 715 bp vlp1 probe in other A1
group members (isolates A2–A4) [15]. The third plasmid,
which hybridised at lower stringency, may carry an A1-
like, but different vlp gene. In isolate A17, which expresses
a different form of variant protein, vlp1B. recurrentis A17 is
found only on the 54 kbp plasmid. Sequence analysis
shows that absolute identity between the two vlp1 copies
in isolate A1 starts 5 nucleotides upstream of the unique
cysteine codon. This cysteine is the N-terminal amino acid
of the mature Vlp1B. recurrentis and is the attachment point
for the lipid modification of the variant protein [17,20].
Upstream of this region the two copies are divergent but
both sequences fit the lipoprotein leader consensus se-
quence. Using oligonucleotides probes specific for these
two leader sequences we demonstrate by Northern analy-
sis that only the vlp1B. recurrentis A1 copy present on the 24
kbp plasmid is expressed in isolate A1. This result suggests
that silent vlp1B. recurrentis A1, carried on a 54 kbp plasmid,
may have undergone a duplicative translocation to the ac-
tive expression site on a 24 kbp plasmid. Of note, 12 the
18 B. recurrentis clinical isolates described to date, one of
which is isolate A17, possess a plasmid migrating in the
region of 24 to 31 kbp [15].
This organisation is similar to that of other relapsing fever
borreliae in which expressed and archived variant protein
genes are located on different plasmids [6,21,22]. In these
borreliae, the use of an animal model of infection has al-
lowed the precise delineation of events taking place dur-
ing an antigenic switch. In B. hermsii, antigenic variation
occurs by replacement of one variable gene with another
downstream from a telomeric promoter. In B. turicatae,
gene conversion is more extensive, involving 10 or more
kilobases downstream of the promoter giving rise to
changes in the size of the plasmid carrying the expression
site [22]. However, a third of B. recurrentis clinical isolates
do not possess a plasmid migrating in the 24 kbp region
[15]. Hence, it is possible that this plasmid was lost during
in vitro cultivation or alternatively, as these isolates ex-
press a major antigen [15], there may exist an expression
site located on a different plasmid. Indeed, activation of
an alternative expression site has already been described
in  B. hermsii[23], utilised for expression of the vector
transmission associated protein Vtp33 [24].
Based on the sequence alignment between silent and ex-
pressed vlp1B. recurrentis A1, it is tempting to speculate that
the recombination site having given rise to expressed vlp1
is located where the two sequences become identical; that
is within the open reading frame itself. Such a model
would be supported by the finding that the probe specific
for the lipoprotein leader sequence of the expressed vlp1B.
recurrentis recognises a message of around 800 bases in RNA
purified from isolate A17. The size of this message is in
agreement with the theoretical size of the major antigen,
Vsp17B. recurrentis A17, expressed by isolate A17 as deter-
mined previously by protein gel electrophoresis [15]. Fur-
ther analysis of sequences from other variant protein
genes should answer this point.
It is not clear how a rapid and successful antigenic switch
is achieved in either B. recurrentis or B. hermsii[25] since
for both species there is an approximately threefold excess
of the expression plasmid compared to the silent plasmid.
Clearly, maintenance and copy number for the two plas-
mids are differentially controlled and this may provide an
opportunity to specifically modulate the copy number of
the silent plasmid prior to a switching event.
The upstream region of both expressed and silent vlp1B. re-
currentis A1 possesses potential promoter sequence, whose
way of functioning remains speculative. Firstly, the ex-
pressed vlp1 contains an unusually long polydT tract that
starts 167 nucleotides from the putative initiating codon.
Shorter polydT tracts closer to the initiating codon (adja-
cent to the -35 region of the promoter) of two lipoprotein
genes of other Borrelia species have been shown to have a
role in transcriptional regulation [26]. It may be that this
region replaces the UP element since such a consensus se-
quence could not be found in these promoters [26]. Un-
like the expressed vlp1B. recurrentis A1 where there is a nearlyBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/25
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perfect UP element consensus sequence there exists a long
polydT tract. Silencing of the archived variant protein
gene copies in B. hermsii is due to the absence of a promot-
er upstream of these genes [6], whereas in B. turicatae
some silent variant protein genes lack promoter features
while others lack both a promoter signature and an initi-
ation codon [22]. Unexpectedly, we find that the silent
copy of vlp1B. recurrentis A1 contains all the features neces-
sary for expression. Although the upstream sequences of
silent and expressed vlp1B. recurrentis A1 are dissimilar, both
copies have a consensus lipoprotein leader sequence and
putative characteristic features of a constitutive promoter.
These observations are based on the assumption that pro-
moters in B. recurrentis are similar to those in Escherichia
coli. However, only mRNA corresponding to the expressed
copy could be detected in isolate A1. It is possible that the
promoter present in the silent copy is not recognised as
functional. An alternative interpretation is that in B. recur-
rentis transcription of the silent copy of the vlp1B. recurrentis
A1 gene is actively repressed. Such a silencing mechanism
to prevent inappropriate expression of a variant protein
gene has not been reported previously for Borreliae
[6,27,28] and may be unique to B. recurrentis. Active re-
pression of surface antigen gene expression has been de-
scribed in trypanosomes and is achieved by telomere
silencing [29] and further investigation is required to de-
termine whether a similar process operates here. In that
context, it would be interesting to pinpoint the location of
the silent vlp1B. recurrentis A1 gene relative to plasmid ends.
Conclusions
The clinical isolate of B. recurrentis, A1, was demonstrated
to contain two copies of a vlp1 gene on plasmids of 54 and
24 kbp. In a further isolate, A17, not expressing this gene,
the  vlp1 gene was only present on a 54 kbp plasmid.
Northern blotting confirmed the expression site was locat-
ed on the 24 kbp plasmid. The cloning and sequencing of
the vlp1B. recurrentis A1 loci have highlighted the broad sim-
ilarities in the organisation of variant protein genes in re-
lapsing fever Borreliae. However this work has also
uncovered some putative features that may be unique to
B. recurrentis and that warrant future studies. Unlike other
relapsing fever Borrelia studied to date, the upstream se-
quences of both silent and expressed genes contain fea-
tures necessary for expression, suggesting the possibility of
control of transcription through a silencing mechanism.
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